Drug Profile
Research programme: capsid protein VP1 therapeutics - Gene Vector Technologies
Alternative Names: BL-4040Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Gene Vector Technologies
- Developer BioLineRx
- Class
- Mechanism of Action Apoptosis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Acute kidney injury
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Acute kidney injury in Israel
- 07 Jul 2011 Preclinical development for Acute kidney injury is ongoing in Israel
- 27 Aug 2007 BL 4040 licensed to Gene Vector Technologies worldwide